Seong Hoon Shin (Seong-Hun Shin, Seong-Hoon Shin)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Small Cell Lung Cancer

Radical Prostatectomy

Prostate Cancer

Top Venues

Integrative cancer therapies

Yonsei medical journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Eunbin Kwag, Soo-Dam Kim, Seong Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa Seung Yoo
A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations. Integrative cancer therapies 23 (2024)
Eunbin Kwag, Soo-Dam Kim, Seong Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa Seung Yoo
A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations. Integrative cancer therapies 23 (2024)
Eunbin Kwag, Soo-Dam Kim, Seong Hoon Shin, Chulho Oak, So-Jung Park, Jun-Yong Choi, Seong Hoon Yoon, In-Cheol Kang, Mi-Kyung Jeong, Hyun Woo Lee, Sun-Hwi Bang, Ji Woong Son, Sanghun Lee, Seung Joon Kim, Hwa Seung Yoo
A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations. Integrative cancer therapies 23 (2024)
Sehhoon Park, Tae Min Kim, Ji-Youn Han, Gyeong-Won Lee, Byoung Yong Shim, Yun-Gyoo Lee, Sang-We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong Hoon Shin, Chan-Young Ock, Byung-Ho Nam, Jaebong Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Kownoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Kyungmin Lee, Jae Lyun Lee
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice. Yonsei medical journal 64 (2) (2023)
Kownoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Kyungmin Lee, Jae Lyun Lee
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice. Yonsei medical journal 64 (2) (2023)
Kownoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Kyungmin Lee, Jae Lyun Lee
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice. Yonsei medical journal 64 (2) (2023)
In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun-Gyoo Lee, Jin Young Kim, Su Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong, Tae-Yong Kim, Sun Young Kim, Hyun Jung Kim, Hyo Jung Kim, Myung Ah Lee, Jung Hye Kwon, Yong Sang Hong, Kyung Hee Lee, Sung Hwa Bae, Dong-Hoe Koo, Jee Hyun Kim, In Sook Woo
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers 13 (2) (2021)
Eun-Ju Ko, Eun-Bin Kwag, Ji Hye Park, So-Jung Park, Ji-Woong Son, Seong-Hun Yoon, Seong Hoon Shin, Hwa-Seung Yoo
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy. Integrative cancer therapies 20 (2021)